natgillin/translations-raw huggingface dataset:
[CYP3A4 substrate, P-gp substrate]
[CYP3A4 substrat, P-gP substrat]
[CYP3A4 substrate; CYP2C19 inhibitor] Norethisterone/ethinylestradi ol (1 mg/0.035 mg QD)
[substrat CYP3A4; inhibitor CYP2C19] noretisteron/etinilestradiol (1 mg/0,035 mg QD)
[CYP3A4 substrate]
[substrat CYP3A4 ]
[CYP3A4 substrates and inhibitors]
[substrati in inhibitorji
[CYP3A4 substrates and inhibitors]
HIV (kot so sakvinavir, amprenavir in nelfinavir)* [substrati in inhibitorji CYP3A4]
[CYP3A4 substrates]
[substrati CYP3A4 ]
[CYP3A4 substrates]
Priporočila glede sočasne uporabe
[CYP3A4 substrates]
Zdravilo
[CYP450 inducer; CYP3A4
[induktor CYP450; zaviralec in
[CYP450 inducer; CYP3A4 inhibitor and substrate]
zaviralec reverzne transkriptaze) [induktor CYP450; zaviralec in substrat CYP3A4]
[CYP450 inducer; P-
[inductor CYP450; induktor
[CYP450 inducer; P-gp inducer] 300 mg TID (co-administered with voriconazole 400 mg single dose)
[induktor CYP450; induktor P-gp] 300 mg TID (sočasno uporabljana z enkratnim 400 mg odmerkom vorikonazola))
[Docefrez 20 mg powder and solvent for concentrate for solution for infusion] Each vial contains
Docefrez 20 mg prašek in vehikel za pripravo koncentrata za infuzijo.
[Docefrez 80 mg powder and solvent for concentrate for solution for infusion] Each vial contains
Docefrez 80 mg prašek in vehikel za pripravo koncentrata za infuzijo.
[eGFR] < 60 ml/min/1.73 m2, see sections 4.4, 4.8, 5.1 and 5.2).
[eGFR] < 60 ml/min/1,73 m2, glejte poglavja 4.4, 4.8, 5.1 in 5.2).
[jejunum and ileum]
tankega [jejunum in
[Justification for not including Braille accepted.]
[Sprejeta je utemeljitev, da Braillova pisava ni potrebna.]
[Justification for not including Braille accepted]
<Sprejeta je utemeljitev, da Braillova pisava ni potrebna.>
[Justification for not including Braille accepted]
[Sprejeta je utemeljitev, da Braillova pisava ni potrebna.]
[MA Number recommended, but not required on the immediate label]
/Številka dovoljenja je priporočljiva, ni pa obvezna na stični ovojnini/
[Mechanism of Interaction]
koagulacijskih testov in ustrezno
[Mechanism of Interaction]
Priporočljiv je natančen nadzor
[Multi-dose bottle]
[Steklenica z več odmerki]
[Multi-dose container:]
Večodmerni vsebnik:
[muscular fatigue and muscular weakness]
[utrujenost in šibkost mišic]
[n = 2], Q30R + H58D [n = 1], M28T + Q30H [n = 1]; for genotype 1b: Y93H [n = 3], Y93H/C [n = 1]).
[n = 1], za genotip 1b: Y93H [n = 3], Y93H/C [n = 1]).
[Not applicable.]
Navedba smiselno ni potrebna.
[Only Carton for bottle:] 2D barcode carrying the unique identifier included.
[Samo za zunanjo ovojnino plastenke:] Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
[Only Carton for bottle:] PC: {number}
[Samo za zunanjo ovojnino plastenke:] PC: {številka}
[potent CYP450 inducer; CYP3A4
[močan induktor CYP450;
[range: 32.0% - 38.9%] and viral infections [range: 1.3% - 17.2%].
32,0 %–38,9 %] in virusne okužbe [razpon: 1,3 %–17,2 %].
[Recommended, but not required on the immediate label]
/Priporočeno, vendar ni obvezno na stični ovojnini/
[St. John’s wort])
[šentjanževka])
[To be provided in the carton]
[Priloženo v škatli]
[UDP-glucuronyl transferase substrate]
[substrat UDP
[UDP-glucuronyl transferase substrate]
[substrat UDP-glukuronil- transferaze]
[Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000)]
[zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/.000), zelo redki (< 1/10.000)]
[Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to ≤1/100); not known (cannot be estimated from the available data)]
[Zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100); neznana (ni mogoče oceniti iz razpoložljivih podatkov)]
^ 400 mg was administered only on Day 3
^ 400 mg odmerek so prejeli samo na dan 3
^ all methicillin-resistant staphylococci should be regarded as resistant to doripenem
^ vse na meticilin rezistentne stafilokoke je treba obravnavati kot odporne na doripenem
^ Blinded independent review (protocol-defined primary analysis)
^ Slepi neodvisni pregled (primarna analiza, določena s protokolom)
^ Data cut-off date of 19 September 2014
^ Presečni datum zbiranja podatkov: 19. september 2014
^ Indicates that grouping of appropriate preferred terms into a single medical concept occurred.
^ Označuje zdruţevanje ustreznih prednostnih izrazov v en sam medicinski koncept.
^ Objective response rate and duration of response are based on IRF-assessed tumour assessments.
^ Objektivni delež odgovora in trajanje odgovora temeljita na IRF-ovi oceni tumorja.
^ Overall survival (OS) analysis includes data from subjects who received placebo + R on study 312-0116 and subsequently received idelalisib in an extension study, based on intent-to-treat analysis.
^ Analiza celokupnega preživetja (OS, overall survival) vključuje podatke oseb, ki so prejemali placebo + R v študiji 312-0116 in so nato v podaljšani študiji prejemali idelalizib (na podlagi analize z-namenom zdravljenja).
^ Quantity of antigen in the final bulk product, according to W.H.O. (TRS 673, 1992)
^ Količina antigena v končnem proizvodu po W.H.O. (TRS 673, 1992)
^ Table 1 shows pooled data from the overall treatment period in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of Perjeta was 24); and from the neoadjuvant treatment period in NEOSPHERE (median number of cycles of Perjeta was 4, across all treatment arms) and TRYPHAENA (median number of cycles of Perjeta was 3 – 6 across treatment arms)
^ Preglednica 1 prikazuje združene podatke celotnega obdobja zdravljenja v preskušanju CLEOPATRA (podatki zbrani do 11. februarja 2014; mediano število ciklov zdravila Perjeta je bilo 24) in iz neoadjuvantnega obdobja zdravljenja v preskušanju NEOSPHERE (mediano število ciklov zdravila Perjeta je bilo 4 v vseh zdravljenih skupinah) in preskušanju TRYPHAENA (mediano število ciklov zdravila Perjeta je bilo 3–6 v vseh zdravljenih skupinah).
^Exploratory Endpoint
^ Eksplorativni opazovani dogodek
^see section 4.8 description of selected adverse reactions
^ Glejte poglavje 4.8 opis izbranih neželenih učinkov.
_ _ 1 Whole virion non-adjuvanted influenza vaccine, inactivated, containing antigen of
_ _ 1 Cepivo proti gripi s celimi inaktiviranimi virioni brez adjuvansa, ki vsebuje antigen
a - AUC(0-) and Cmax based on population PK post-hoc estimates.
a – Vrednosti AUC(0-) in Cmax na osnovi post-hoc ocene populacijske farmakokinetike.
A 0.2 or 0.22 micron low protein-binding filter must be on line between the patient and the infusion port.
Na liniji med bolnikom in infuzijskim vhodom mora biti nameščen 0,2– ali 0,22–mikronski filter, ki veže beljakovine z nizko molekulsko maso.
a 0.6 ml = maximum delivered volume per vial (Xolair 75 mg).
a 0,6 ml = največji injicirani volumen na vialo (Xolair 75 mg).
A 1 mg blister of inhaled insulin is approximately equivalent to 3 IU of subcutaneously injected fast- acting human insulin.
1-mg pretisni omot inhaliranega insulina ustreza približno 3 i.e. subkutano injiciranega hitrodelujočega humanega insulina.
A 1 mL graduated syringe with 19 Gauge or wider needle should be used for withdrawing the solvent from its vial.
Za izvleko vehikla iz viale je treba uporabiti 1 ml graduirano injekcijsko brizgo velikosti 19 G ali večjo.
a 1 ml sterile syringe an injection needle (30G x ½″).
1-mililitrska sterilna brizga injekcijska igla (30G x ½″).
a 1 ml syringe a long needle to withdraw Pegasys from the vial
1 ml injekcijska brizga, dolga igla za odvzem zdravila Pegasys iz viale,
a 1 ml syringe;
1 ml brizgo;
A 1-year study in 10-12 weeks old dogs demonstrated findings in the adrenal gland (focal inflammation and degeneration in the glucocorticoid-producing regions of the cortex) and a mild compromise of cortisol production after exogenous stimulation with adrenocorticotropic hormone.
1-letna študija pri psih, starih od 10–12 tednov, je pokazala spremembe v nadledvični žlezi (žariščno vnetje in degeneracija predelov skorje, kjer nastajajo glukokortikoidi) in manjši negativen vpliv na proizvodnjo kortizola po eksogeni stimulaciji z adrenokortikotropnim hormonom.
A 1.3-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months (1.58 per 100 person- years) compared to thalidomide in combination with melphalan and prednisone (1.19 per 100 person-years).
Pri bolnikih, ki so prejemali lenalidomid v kombinaciji z deksametazonom do napredovanja bolezni ali 18 mesecev dolgo, so opazili 1,3-kratno zvečanje incidence SPM s čvrstimi tumorji (1,58 na 100 oseb- let) v primerjavi s talidomidom v kombinaciji z melfalanom in prednizonom (1,19 na 100 oseb-let).
a 10 mg/kg every 2 weeks b Relative to control arm
a 10 mg/kg vsaka 2 tedna b glede na kontrolno skupino
A 10 minute PET image should be acquired starting approximately 30 to 50 minutes after intravenous injection of Amyvid.
Desetminutno slikanje s PET začnite približno 30 do 50 minut po intravenskem injiciranju zdravila Amyvid.
A 10 ml graduated dosing syringe and adapter are also provided in the pack
V škatli je priložena tudi 10 ml umerjena odmerna brizga in nastavek.
A 10 ml graduated dosing syringe and adapter are also provided in the pack
V škatlici je priložena tudi 10 ml umerjena odmerna brizga in nastavek.
A 100 mL infusion bag can be used to prepare the infusion, based on the patient’s volume requirements.
Za pripravo infuzije je mogoče uporabiti 100-ml infuzijsko vrečko glede na količino, ki jo potrebuje bolnik.
A 12-week phase III clinical study performed in patients with type 1 diabetes mellitus receiving insulin glargine as basal therapy indicate that the immediate post-meal administration of insulin glulisine provides efficacy that was comparable to immediate pre-meal insulin glulisine (0-15 minutes) or regular insulin (30-45 minutes).
12-tedenska klinična študija faze III pri bolnikih z diabetesom mellitusom tipa 1, ki so kot bazalno terapijo dobivali insulin glargin, kaže, da apliciranje insulina glulisin takoj po obroku zagotavlja primerljivo učinkovitost kot uporaba insulina glulisin tik (0–15 minut) pred obrokom ali navadnega humanega insulina 30–45 minut pred obrokom.
A 12-week, multi-centre, randomised, double-blind, placebo-controlled study was conducted to evaluate the treatment effect of saxagliptin 2.5 mg once daily compared with placebo in 170 patients (85 patients on saxagliptin and 85 on placebo) with type 2 diabetes (HbA1c 7.0-11%) and renal impairment (moderate [n=90]; severe [n=41]; or ESRD [n=39]).
Izvedena je bila 12-tedenska multicentrična, randomizirana, dvojno slepa, s placebom kontrolirana študija za oceno učinka zdravljenja s saksagliptinom 2,5 mg enkrat na dan v primerjavi s placebom pri 170 bolnikih (85 bolnikov na saksagliptinu in 85 na placebu) s sladkorno boleznijo tipa 2 (HbA1c 7,0– 11 %) in okvaro ledvic (zmerno [n=90], hudo [n=41] ali končno odpovedjo ledvic [n=39]).
A 14 year-old girl who was treated for Cushing’s disease with ketoconazole 200 mg twice daily presented one month later with jaundice, fever anorexia, nausea and vomiting.
Pri 14-letni deklici, ki se je zaradi Cushingovega sindroma zdravila z 200 mg ketokonazola dvakrat na dan, so se pojavili zlatenica, povišana telesna temperatura, anoreksija, navzea in bruhanje.
A 14-week, open-label treatment was available for a subset of patients who completed the double-blind period.
Podskupina bolnikov, ki so končali dvojno slepo obdobje, je sodelovala v 14-tedenskem odprtem preskušanju.
A 14C-darunavir trial in healthy volunteers showed that a majority of the radioactivity in plasma after a single 400/100 mg darunavir with ritonavir dose was due to the parent active substance.
Preskušanje z uporabo darunavirja označenega s 14C pri zdravih prostovoljcih, je pokazalo, da je bila večina radioaktivnosti, izmerjene v plazmi po enkratnem 400/100 mg odmerku darunavirja z ritonavirjem posledica matične učinkovine.
A 14C-lopinavir study in humans showed that 89% of the plasma radioactivity after a single 400/100 mg lopinavir/ritonavir dose was due to parent active substance.
Študija s 14C-lopinavirjem pri ljudeh je pokazala, da gre 89% radioaktivnosti v plazmi po enkratnem odmerku 400 mg/100 mg lopinavirja/ritonavirja na račun matične zdravilne učinkovine.
A 15 minute infusion time has not been studied in cancer patients with a creatinine clearance of
15 minutne infuzije pri bolnikih z rakom, ki imajo očistek kreatinina < 50 ml/min, niso proučevali.
A 15 minute infusion time has not been studied in cancer patients with CLCr <50 mL/min.
15 minutne infuzije pri bolnikih z rakom, ki imajo očistek kreatinina < 50 ml/min, niso proučevali.
A 15 minute infusion time has not been studied in cancer patients with CLCr <50 mL/min.
15-minutne infuzije pri bolnikih z rakom, ki imajo očistek kreatinina < 50 ml/min, niso proučevali.
A 15 minute infusion time has not been studied in cancer patients with CLCr <50 mL/min.
minutne infuzije pri bolnikih z rakom, ki imajo očistek kreatinina < 50 ml/min, niso proučevali.
A 150 ml bottle with a 1 ml oral syringe (delivering up to 100 mg levetiracetam) graduated every 0.05 ml (corresponding to 5 mg)
150 ml steklenica z 1 ml brizgo za peroralno uporabo (ki vsebuje do 100 mg levetiracetama) z oznako za vsakih 0,05 ml (kar ustreza 5 mg).
A 150 ml bottle with a 3 ml oral syringe (delivering up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg)
150 ml steklenica s 3 ml brizgo za peroralno uporabo (ki vsebuje do 300 mg levetiracetama) z oznako za vsak 0,1 ml (kar ustreza 10 mg).
A 150 ml bottle with a 3 ml oral syringe (delivering up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg)
150 ml steklenica s 3 ml graduirano brizgo za peroralno uporabo (ki vsebuje do 300 mg levetiracetama) z oznako za vsak 0,1 ml (kar ustreza 10 mg).
A 17 years old girl was treated on ketoconazole 1200 mg/day for an adrenal carcinoma with liver metastasis and had altered liver function tests at 22 days.
Pri 17-letni deklici, ki se je zaradi adrenalnega karcinoma z jetrno metastazo zdravila z 1200 mg ketokonazola/dan, so po 22 dneh ugotovili spremenjene vrednosti preiskav delovanja jeter.
A 2 litre and 10 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection.
2-litrska in 10-litrska aluminijasta jeklenka (prepoznate jo po zelenomodrem vratu in belem telesu), napolnjena pod tlakom 155 bar, opremljena z nadtlačnim (presežnotlačnim) ventilom iz nerjavečega jekla s specifičnim izhodnim priključkom.
a 2 ml syringe;
2 ml brizgo;
A 2 to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving oestrogens has been reported (see section 4.8).
Pri ženskah v postmenopavzi, ki so prejemale estrogene, so poročali o 2- do 4-kratnem zvečanju tveganja za bolezen žolčnika, pri kateri je potreben kirurški poseg (glejte poglavje 4.8).
A 2-fold increase of ticagrelor exposure was observed after daily consumption of large quantities of grapefruit juice (3x200 ml).
Po vsakodnevnem zaužitju večjih količin grenivkinega soka (3 200 ml) je bilo opaženo 2-kratno povečanje izpostavljenosti ticagrelorju.
A 2-pronged polycarbonate applicator tip.
2-krak polikarbonaten aplikacijski nastavek
a 2-sided unstratified log-rank test b Fisher’s Exact test
a 2-stranski nestratificiran log-rang test b Fisherjev eksaktni test
A 2-year carcinogenicity study in mice showed an increased combined incidence of hepatocellular adenomas and carcinomas in males, but not in females, at plasma concentrations about 2 to 4 times the plasma concentrations achieved at the therapeutic dose in humans.
Dvoletna študija kancerogenosti pri miših je pokazala povečanje incidence hepatocelularnih adenomov in karcinomov pri samcih, ne pa pri samicah, pri plazemskih koncentracijah, približno 2- do 4-krat višjih od plazemskih koncentracij, doseženih pri ljudeh po terapevtskih odmerkih.
A 2.12-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide (9 cycles) in combination with melphalan and prednisone (1.57 per 100 person-years) compared with melphalan in combination with prednisone (0.74 per 100 person-years).
Pri bolnikih, ki so prejemali lenalidomid (9 ciklov) v kombinaciji z melfalanom in prednizonom, so opazili 2,12-kratno zvečanje incidence SPM s čvrstimi tumorji (1,57 na 100 oseb-let) v primerjavi z melfalanom v kombinaciji s prednizonom (0,74 na 100 oseb-let).
A 20 mg capsule is also available.
Na voljo so tudi 20 mg kapsule.
A 20 ml measuring cup is provided in the pack.
V zloženki je priložen 20 ml odmerni lonček.
A 20% heart rate reduction, without bradycardia, was achieved by 69.9% of patients in the ivabradine group versus 12.2% in the placebo group during the titration period of 2 to 8 weeks (Odds Ratio: E = 17.24, 95% CI [5.91 ; 50.30]).
Znižanje srčne frekvence za 20 % brez bradikardije so dosegli pri 69,9 % bolnikov iz skupine, ki je prejemala ivabradin, v primerjavi z znižanjem za 12,2 % v skupini, ki je prejemala placebo med obdobjem povečevanja odmerka, ki je trajalo 2–8 tednov (razmerje obetov: E = 17,24, 95% IZ [5,91; 50,30]).
A 20% increase in body weight resulted in an approximate 18.5% increase in clearance.
Za 20 % večja telesna masa je povzročila približno 18,5 % povečanje očistka.
A 20-minute PET image should be acquired starting at approximately 90 minutes after intravenous injection of florbetaben (18F).
20-minutno slikanje s PET začnite približno 90 minut po intravenskem injiciranju [18F]florbetabena.
A 22- to 26-gauge needle is recommended.
Priporočljive so igle od številke 22 do 26.
A 24- month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder.
24 mesecev trajajoča mehanska raziskava na samcih podgan je pokazala, da je dajanje pioglitazona povzročilo povečano incidenco hiperplastičnih sprememb v mehurju.
A 24-week active (metformin)-controlled study was designed to evaluate the efficacy and safety of sitagliptin 100 mg once daily (N=528) compared to metformin (N=522) in patients with inadequate glycaemic control on diet and exercise and who were not on anti-hyperglycaemic therapy (off therapy for at least 4 months).
Zasnovana je bila 24-tedenska z zdravilno učinkovino (metforminom) nadzorovana študija, v kateri so vrednotili učinkovitost in varnost sitagliptina v odmerku 100 mg enkrat na dan (N=528) v primerjavi z metforminom (N=522) pri bolnikih, pri katerih urejenost glikemije z dieto in s telesno vadbo ni bila zadostna in ki niso bili na antihiperglikemičnem zdravljenju (brez zdravljenja vsaj 4 mesece).
A 24-week parallel group study was conducted in 125 children with type 1 diabetes mellitus aged 2 to
Študija je zajela 125 otrok s sladkorno boleznijo tipa 1, starih od 2 do 6 let.
A 24-week placebo-controlled study was conducted to evaluate the efficacy and safety of linagliptin (5 mg once daily) added to insulin with or without metformin.
V s placebom nadzorovani 24-tedenski študiji so ocenili učinkovitost in varnost linagliptina (5 mg enkrat na dan), dodanega h insulinu z ali brez metformina.
A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to glimepiride (alone or in combination with metformin).
Zasnovana je bila 24-tedenska s placebom nadzorovana študija, v kateri so vrednotili učinkovitost in varnost sitagliptina (100 mg enkrat na dan), če so ga dodali glimepiridu (samemu ali v kombinaciji z metforminom).
A 24-week study was conducted to evaluate the efficacy and safety of saxagliptin 5 mg in combination with metformin as initial combination therapy in treatment-naive patients with inadequate glycaemic control (HbA1c 8-12%).
Opravljena je bila 24-tedenska študija za oceno učinkovitosti in varnosti 5 mg saksagliptina v kombinaciji z metforminom kot uvodnim kombiniranim zdravljenjem pri bolnikih, ki še niso dobivali zdravil in so imeli nezadostno urejeno glikemijo (HbA1c 8-12 %).
A 24-week study was conducted to evaluate the efficacy and safety of saxagliptin 5 mg in combination with metformin as initial combination therapy in treatment-naïve patients with inadequate glycaemic control (HbA1c 8-12%).
Narejena je bila 24-tedenska študija za oceno učinkovitosti in varnosti 5 mg saksagliptina v kombinaciji z metforminom kot uvodnega kombiniranega zdravljenja pri bolnikih, ki še niso bili zdravljeni in niso imeli ustrezno urejene glikemije (HbA1c 8 % -12 %).
A 25 mg strength of Enbrel is available for doses of 25 mg (or less).
Za 25 mg odmerek (ali za manjše odmerke) je na voljo zdravilo Enbrel jakosti 25 mg.
A 25 mg strength of Enbrel is available for doses of 25 mg.
Za 25 mg odmerek je na voljo zdravilo Enbrel jakosti 25 mg.
A 250 ml, 100 ml or 50 ml infusion bag can be used to prepare the infusion, based on the patient’s volume requirements.
Za pripravo infuzije se lahko uporabi 250-ml, 100-ml ali 50-ml infuzijsko vrečko, odvisno od bolnikovih zahtev glede infundiranega volumna.
A 26 week, double blind, randomised clinical trial was conducted to investigate the efficacy and safety of adding liraglutide (1.8 mg) vs. placebo in patients with type 2 diabetes inadequately controlled on basal insulin with or without metformin.
V 26-tedenskem, dvojno slepem, randomiziranem kliničnem preskušanju so vrednotili učinkovitost in varnost liraglutida (1,8 mg) v primerjavi s placebom pri bolnikih s sladkorno boleznijo tipa 2 z nezadostno urejeno glikemijo pri zdravljenju z bazalnim insulinom, z metforminom ali brez njega.
A 26-week phase III clinical study followed by a 26-week extension safety study was conducted to compare insulin glulisine (0-15 minutes before a meal) with regular human insulin (30-45 minutes before a meal) injected subcutaneously in patients with type 2 diabetes mellitus also using NPH insulin as basal insulin.
26-tedenska klinična študija faze III, kateri je sledila 26-tedenska nadaljevalna študija varnosti, je primerjala insulin glulisin (0–15 minut pred obrokom) z navadnim humanim insulinom (30–45 minut pred obrokom), injiciranima subkutano, in sicer pri bolnikih z diabetesom mellitusom tipa 2, ki so uporabljali tudi insulin NPH kot bazalni insulin.
A 27 gauge needle is recommended for the administration of denosumab.
Za dajanje denosumaba je priporočljivo uporabiti iglo številka 27.
A 27 gauge needle is recommended for the administration of denosumab.
Za injiciranje denosumaba je priporočljivo uporabiti iglo številka 27.
A 3 mg blister of inhaled insulin is approximately equivalent to 8 IU of subcutaneously injected fast-acting human insulin.
3-mg pretisni omot inhaliranega insulina ustreza približno 8 i.e. subkutano injiciranega hitrodelujočega humanega insulina (glejte poglavje 5.2).
A 3 ml oral dispenser (graduated in 0.1 ml steps) should be used for dosing children 0 - 12 months of age requiring 1 ml to 3 ml of Tamiflu 6 mg/ml oral suspension.
Pri odmerjanju otrokom, starim od 0 do 12 mesecev, ki potrebujejo 1 ml do 3 ml zdravila Tamiflu mg/ml peroralne suspenzije, je potrebno uporabiti 3-ml peroralni odmernik (z oznakami po 0,1 ml).
A 3 ml polypropylene syringe with a silicone O-ring fitted to the plunger.
3- mililitrska polipropilenska brizga s silikonskim tesnilnim obročkom, nameščenim na bat
A 30 mg intravenous bolus immediately followed by a 1 mg/kg subcutaneous every 12 hours provided initial peak anti-Factor Xa levels of 1.16 IU/mL (n=16) and average exposure corresponding to 88% of steady state levels.
Zdravljenje s 30-mg intravenskim bolusom, ki mu je neposredno sledila subkutana uporaba odmerka 1 mg/kg na 12 ur, je zagotovilo začetno najvišjo koncentracijo anti-Xa 1,16 i.e./ml (n = 16) in povprečno izpostavljenost, ki ustreza 88 % koncentracije v stanju dinamičnega ravnovesja.
a 30 micrograms per kilogram body weight by injection, followed immediately by
30 mikrogramov na kilogram telesne mase z injekcijo, ki mu takoj sledijo